A recent article shows patient safety concerns about PPI’s are common and strongly associated with attempts at discontinuation, with or without a provider’s recommendation. Patients at high risk for GI bleeding, who clearly benefit from PPI’s, were just as likely to have tried stopping PPI’s as others. Physicians should always discuss the risks and benefits
Research recently published in the seminal journal Gastroenterology failed to find evidence of alterations in key markers of bone formation and metabolism in postmenopausal women on PPI’s. The study examined calcium absorption, serum or urine mineral levels, parathyroid hormone, Vitamin D status, or bone-mineral density with 6 months of PPI therapy. The prospective double-blind study
Proton pump inhibitor therapy is not connected to an increased risk of cardiovascular disease, according to a study published in Alimentary Pharmacology & Therapeutics. The FDA has discouraged using PPI’s with antiplatelet therapy clopidogrel because the drugs work with the same isoenzyme. “Inhibition of CYP2C19 by PPIs may reduce the bioavailability of the active metabolites of
From the AGA website, here is a nice review of the data thus far and how to alleviate your patients’ concerns. See the AGA review here.
